Part of the reason we very specifically put in post-market surveillance measures, once these products have been approved, is that you're actually looking for those adverse events in a very controlled way in clinical trials.
Beyond the regular reporting, there are actually tens of thousands of women who would be involved in clinical trials, and those adverse reactions would be reported as part of the commitments. It's actually seen to be a more effective way to gather information on adverse reactions than voluntary reporting.